Boehringer Ingelheim

For Healthcare Professionals

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Area

Section Overview

Metabolic

Oncology

Respiratory

Inflammation
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See all products

Products

See all products
Resources
Contact
Logout

Boehringer Ingelheim

Glyxambi
CV Risk Protection
Tools & Apps
5 years of EMPA-REG Outcome
Let's Talk
Prof Christoph Wanner’s take on EMPA-KIDNEY
Prescribing Information
Voice of CRM
Videos

voice of crm

Optimize RAASi Dose with SGLT2i

23/07/2024 | Author: Boehringer Ingelheim

Document ID: PC-SG-102513

Voice of CRM

PEKP||Primary Care Physicians to Transform CKD Prognosis

PEKP||EMPA-KIDNEY: Benefits of Empagliflozin for A1 & A2

PEKP||Synergistic Relationship between RAASi and SGLT2i

PEKP||Optimize RAASi Dose with SGLT2i

PEKP||The Role of Screening in CKD Patient Outcomes

PEKP||Initiating SGLT2i in Low eGFR Patients

PEKP||eGFR Slope as a Surrogate Endpoint in Kidney Trials

PEKP||VoCRM Video - Managing Initial eGFR Dip

VoCRM||What is the clinical relevance of broader patient population studied in EMPA-KIDNEY?

VoCRM||How are CRM conditions linked?

RELATED CONTENT

PC-SG-102514-thumbnail

1:15

PEKP||Primary Care Physicians to Transform CKD Prognosis

Watch now Opens in new tab

PC-SG-102510-thumbnail

1:25

PEKP||EMPA-KIDNEY: Benefits of Empagliflozin for A1 & A2

Watch now Opens in new tab

PC-SG-102509-thumbnail

1:12

PEKP||Synergistic Relationship between RAASi and SGLT2i

Watch now Opens in new tab

PC-SG-102512-thumbnail

1:06

PEKP||The Role of Screening in CKD Patient Outcomes

Watch now Opens in new tab

PC-SG-102511-thumbnail

1:09

PEKP||Initiating SGLT2i in Low eGFR Patients

Watch now Opens in new tab

PC-SG-102508-thumbnail

1:16

PEKP||eGFR Slope as a Surrogate Endpoint in Kidney Trials

Watch now Opens in new tab

Pagination

Load more

Home
Metabolic
Empagliflozin
Voice of CRM
PEKP||Optimize RAASi Dose with SGLT2i

Sitemap

Therapeutic Area

Resources

BI logo

Privacy
Terms of use
Sitemap
Contact

This website is intended for healthcare professionals in Singapore. The contents of this website are for information purposes only and are not intended to substitute for advice, treatment or recommendations of a healthcare professional. For your health concerns and other questions about symptoms, treatment or medication, consult a healthcare professional.

Copyright © 2025 Boehringer Ingelheim Singapore Pte. Ltd.
All rights reserved. Use of this Site is subject to the Terms of Use and Privacy Statement.